A.B. (2007). Presynaptic Inhibition of GABAA receptor-mediated unitary IPSPs
by cannabinoid receptors at synapses between CCK-positive interneurons in rat hippocampus.
J Neurophysiol. 98(2), 861-9.
Arevalo, C., de Miguel, R., & Hernandez-Tristan, R. (2001). Cannabinoid effects
on anxiety-related behaviours and hypothalamic neurotransmitters. Pharmacology,
Biochemistry and Behavior, 70 (1), 123-131.
Bambico, F.R., Katz, N., Debonnel, G., & Gobbi, G. (2007). Cannabinoids elicit
antidepressant-like behavior and activate serotonergic neurons through the medial
prefrontal cortex. J Neurosci., 27(43), 11700-11.
Biala, G., Kruk, M., & Budzynska, B. (2009). Effects of the cannabinoid receptor
ligands on anxiety-related effects of d-amphetamine and nicotine in the mouse elevated
plus maze test. J Physiol Pharmacol., 60(2), 113-22.
Bortolato, M., Campolongo, P., Mangieri. R.A., Scattoni, M.L., Frau, R., et.al.
(2006). Anxiolytic-like properties of the anandamide transport inhibitor AM404.
Neuropsychopharmacology. 31(12), 2652-9.
Bucherelli, C., Baldi, E., Mariottini, C., Passani, M.B., & Blandina, P. (2006).
Aversive memory reactivation engages in the amygdala only some neurotransmitters
involved in consolidation. Learn Mem.,13(4), 426-30.
Cannich, A., Wotjak, C.T., Kamprath, K., Hermann, H., Lutz, B., et.al. (2004). CB1
cannabinoid receptors modulate kinase and phosphatase activity during extinction
of conditioned fear in mice. Learn Mem.,11(5), 625-32.
Carlson, E.T. (1974). Cannabis indica in 19th-century psychiatry. American Journal
of Psychiatry. 131(9), 1004-7
Chhatwal, J.P., Davis, M., Maguschak, K.A., & Ressler, K.J. (2005). Enhancing
cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology,
30(3), 516-24.
Crippa, J.A., Zuardi, A.W., Garrido, G.E., Wichert-Ana, L., Guarnieri, R., et.al.
(2004). Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology,
29(2), 417-26.
Curtis, A., Rickards, H. (2006). Nabilone could treat chorea and irritability in
Huntington's disease. J Neuropsychiatry Clin Neurosci.,18(4), 553-4.
Dean, B., Sundram, S., Bradbury, R., Scarr, E., & Copolov, D. (2001). Studies
on [ 3 h]cp-55940 binding in the human central nervous system: regional specific
changes in density of cannabinoid-1 receptors associated with schizophrenia and
cannabis use. Neuroscience. 103 (1), 9-15, 2001.
Deutsch, S.I., Rosse, R.B., Connor, J.M., Burket, J.A., Murphy, M.E., et.al. (2008).
Current status of cannabis treatment of multiple sclerosis with an illustrative
case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia,
and marijuana dependence treated with dronabinol. CNS Spectr., 13(5),393-403.
D'Souza, D.C., Perry, E., MacDougall, L., Ammerman, Y., Cooper, T., et.al. (2004).
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy
individuals: implications for psychosis. Neuropsychopharmacology, 29(8),
1558-72.
Emrich, H.M., Leweke, F.M. & Schneider, U. (1997). Towards a cannabinoid hypothesis
of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid
system. Pharmacology, Biochemistry & Behavior, 56(4), 803-7.
Fritzsche, M. (2000). Are cannabinoid receptor knockout mice animal models for schizophrenia?
Medical Hypotheses, 56(6), 638-643.
Fujiwara, M. & Egashira, N. (2004). New perspectives in the studies on endocannabinoid
and cannabis: Abnormal behaviors associate with CB1 cannabinoid receptor and development
of therapeutic application. J Pharmacol Sci., 96(4), 362–6.
Giuffrida, A., Leweke, F.M., Gerth, C.W., Schreiber, D., Koethe, D. et.al (2004).
Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely
correlated with psychotic symptoms. Neuropsychopharmacology, 29(11), 2108-14.
Gobbi, G., Bambico, F.R., Mangieri, R., Bortolato, M., Campolongo, P., et.al. (2005).
Antidepressant-like activity and modulation of brain monoaminergic transmission
by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A, 102(51),
18620-5.
González-Cuevas, G., Aujla, H., Martin-Fardon, R., López-Moreno, J.A., Navarro,
M., et.al. (2007). Subchronic cannabinoid agonist (WIN 55,212-2) treatment during
cocaine abstinence alters subsequent cocaine seeking behavior. Neuropsychopharmacology,
32(11), 2260-6.
Haller, J., Mátyás, F., Soproni, K., Varga, B., Barsy, B., et.al. (2007). Correlated
species differences in the effects of cannabinoid ligands on anxiety and on GABAergic
and glutamatergic synaptic transmission. Eur J Neurosci., 25(8), 2445-56.
Hill, M.N., Ho, W.S., Sinopoli, K.J., Viau, V., Hillard, C.J., & Gorzalka, B.B.
(2006). Involvement of the endocannabinoid system in the ability of long-term tricyclic
antidepressant treatment to suppress stress-induced activation of the hypothalamic-pituitary-adrenal
axis. Neuropsychopharmacology, 31(12), 2591-9.
Hill, M.N., Karacabeyli, E.S., & Gorzalka, B.B. (2007). Estrogen recruits the
endocannabinoid system to modulate emotionality. Psychoneuroendocrinology,
32(4), 350-7.
Jiang, W., Zhang, Y., Xiao, L., Van Cleemput, J., Ji, S.P., et.al. (2005). Cannabinoids
promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and
antidepressant-like effects. J Clin Invest., 115(11), 3104-16.
Kamprath, K., Marsicano, G., Tang, J., Monory, K., & Bisogno, T. (2006). Cannabinoid
CB1 receptor mediates fear extinction via habituation-like processes. J Neurosci.,
26(25), 6677-86.
Kathuria, S., Gaetani, S., Fegley, D., Valino, F., Duranti, A. et al. (2003). Modulation
of anxiety through blockade of anandamide hydrolysis. Nature Medicine,
9(1), 76-81.
Kim, K.W., Jo, Y.H., Zhao, L., Stallings, N.R., Chua, S.C. Jr, et.al. (2008). Steroidogenic
factor 1 regulates expression of the cannabinoid receptor 1 in the ventromedial
hypothalamic nucleus. Mol Endocrinol., 22(8), 1950-61.
Laviolette, S.R. & Grace, A.A. (2006). Cannabinoids Potentiate Emotional Learning
Plasticity in Neurons of the Medial Prefrontal Cortex through Basolateral Amygdala
Inputs. J Neurosci. 2006 26(24), 6458-68.
Leweke, F.M., Giuffrida, A., Wurster, U., Emrich, H.M., & Piomelli, D. (1999).
Elevated endogenous cannabinoids in schizophrenia. NeuroReport 10, 1665-1669.
Lin, H.C., Mao, S.C., & Gean, P.W. (2006). Effects of intra-amygdala infusion
of CB1 receptor agonists on the reconsolidation of fear-potentiated startle. Learn
Mem., 13(3), 316-21.
Long, L.E., Malone, D.T., & Taylor, D.A. (2006). Cannabidiol reverses MK-801-induced
disruption of prepulse inhibition in mice. Neuropsychopharmacology, 31(4),
795-803.
Mangieri, R.A., Hong, K.I., Piomelli, D., & Sinha, R. (2009). An endocannabinoid
signal associated with desire for alcohol is suppressed in recently abstinent alcoholics.
Psychopharmacology (Berl)., 205(1), 63-72.
Mangieri, R.A. & Piomelli, D. (2007).Enhancement of endocannabinoid signaling
and the pharmacotherapy of depression. Pharmacol Res., 56(5), 360-6.
Martin, M., Ledent, C., Parmentier, M., Maldonado, R., & Valverde, O. (2002).
Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology
(Berl), 159(4), 379-87.
Melis, M. & Pistis, P. (2007). Endocannabinoid signaling in midbrain dopamine
neurons: more than physiology? Curr Neuropharmacol., 5(4), 268-77.
Meltzer, H.Y., Arvanitis, L., Bauer, D., & Rein, W. (2004). Placebo-controlled
evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective
disorder. Am J Psychiatry, 161(6), 975-84.
Miczek, K.A. (1978). D-Tetrahydrocannabinol: Antiaggressive Effects in Mice, Rats,
and Squirrel Monkeys. Science, 199, 1459-61.
Moreira, F.A. & Crippa, J.A. (2009). The psychiatric side-effects of rimonabant.
Rev Bras Psiquiatr., 31(2), 145-53.
Moreira, F.A. (2007). Serotonin, the prefrontal cortex, and the antidepressant-like
effect of cannabinoids. J Neurosci., 27(49), 13369-70.
Moreira, F.A., Aguiar, D.C., Campos, A.C., Lisboa, S.F., Terzian, A.L., et.al.,
(2009). Antiaversive effects of cannabinoids: is the periaqueductal gray involved?
Neural Plast. 2009:625469. Epub 2008 Dec 2., doi:10.1155/2009/625469
Morgan, C.J. & Curran, H.V. (2008). Effects of cannabidiol on schizophrenia-like
symptoms in people who use cannabis. Br J Psychiatry, 192(4), 306-7.
Muller-Vahl, K.R., Koblenz, A., Jöbges, M., Kolbe, H., Emrich, H.M., et.al. (2001).
Influence of Treatment of Tourette Syndrome with D 9 -Tetrahydro-cannabinol (D 9
-THC) on Neuropsychological Performance. Pharmacopsychiatry 34 (1), : 19-24
Müller-Vahl, K.R., Schneider, U., Koblenz, A., Jöbges, M., Kolbe, H., et.al., (2002).
Treatment of Tourette's syndrome with delta-9-THC): A randomized crossover trial.
Pharmacopsychiatry, 35(2), 57-61.
Naderi, N., Haghparast, A., Saber-Tehrani, A., Rezaii, N., Alizadeh, A.M., et.al.,
(2008). Interaction between cannabinoid compounds and diazepam on anxiety-like behaviour
of mice. Pharmacol Biochem Behav., 89(1), 64-75.
Ottani, A., Ferrari, F., Giuliani, D., (2002). Neuroleptic-like profile of the cannabinoid
agonist, HU 210, on rodent behavioural models. Progress in Neuro-Psychopharmacology
& Biological Psychiatry. 26(1), 91- 96.
Pacher, P., Bátkai, S., & Kunos, G. (2006). The endocannabinoid system as an
emerging target of pharmacotherapy. Pharmacol Rev., 58(3), 389-462.
Panlilio, L.V., Solinas, M., Matthews, S.A., & Goldberg, S.R. (2007). Previous
exposure to THC alters the reinforcing efficacy and anxiety-related effects of cocaine
in rats. Neuropsychopharmacology, 32(3), 646-57.
Patel, S. & Hillard, C.J. (2006). Pharmacological evaluation of cannabinoid
receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic
role for endogenous cannabinoid signaling. J Pharmacol Exp Ther., 318(1),
304-11.
Patel, S., Roelke, C.T., Rademacher, D.J., Cullinan, W.E., & Hillard, C.J. (2004).
Endocannabinoid signaling negatively modulates stress-induced activation of the
hypothalamic-pituitary-adrenal axis. Endocrinology, 145(12), 5431-8.
Patel, S., Cravatt, B.F., & Hillard, C.J. (2005). Synergistic interactions between
cannabinoids and environmental stress in the activation of the central amygdala.
Neuropsychopharmacology, 30(3), 497-507.
Patel, S., Hillard, C.J. (2008). Adaptations in endocannabinoid signaling in response
to repeated homotypic stress: a novel mechanism for stress habituation. Eur J Neurosci.,
27(11), 2821-9.
Phan, K.L., Angstadt, M., Golden, J., Onyewuenyi, I., Popovska, A., et.al. (2008).
Cannabinoid modulation of amygdala reactivity to social signals of threat in humans.
J Neurosci., 28(10), 2313-9.
Polli, G. (1972). Haschish in melancholia. 1874. Medical Times, 100(7),
236-8.
Robinson, L., Goonawardena, A.V., Pertwee, R.G., Hampson, R.E., & Riedel, G.
(2007). The synthetic cannabinoid HU210 induces spatial memory deficits and suppresses
hippocampal firing rate in rats. Br J Pharmacol., 151(5), 688-700.
Robson, P. (2001). Therapeutic aspects of cannabis and cannabinoids. Br J Psychiatry.
178, 107-15.
Rodríguez de Fonseca, F., Del Arco, I., Bermudez-Silva, F.J., Bilbao, A., Cippitelli,
A., et.al. (2005). The endocannabinoid system: physiology and pharmacology. Alcohol
Alcohol, 40(1), 2-14.
Rubino, T., Sala, M., Viganò, D., Braida, D., Castiglioni, C., et.al. (2007). Cellular
mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol
in rats. Neuropsychopharmacology, 32(9), 2036-45.
Rutkowska, M., Jamontt, J., & Gliniak, H. (2006). Effects of cannabinoids on
the anxiety-like response in mice. Pharmacol Rep., 58(2), 200-6.
Scher, J. (1971). Marijuana as an agent in rehabilitating alcoholics. American Journal
of Psychiatry, 127(7), 971-2.
Scherma, M., Medalie, J., Fratta, W., Vadivel, S.K., Makriyannis, A., et.al. (2008).
The endogenous cannabinoid anandamide has effects on motivation and anxiety that
are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology,
54(1), 129-40.
Schwarcz, G., Karajgi, B., & McCarthy, R. (2009). Synthetic delta-9-tetrahydrocannabinol
(dronabinol) can improve the symptoms of schizophrenia. J Clin Psychopharmacol.,
29(3), 255-8.
Serra, G., Fratta, W. (2007). A possible role for the endocannabinoid system in
the neurobiology of depression. Clin Pract Epidemol Ment Health., 3:25.
doi:10.1186/1745-0179-3-25.
Snider, N.T., Sikora, M.J., Sridar, C., Feuerstein, T.J., Rae, J.M., et.al. (2008).
The endocannabinoid anandamide is a substrate for the human polymorphic cytochrome
P450 2D6. J Pharmacol Exp Ther., 327(2), 538-45.
Stockings, G.T, (1947). A New Euphoriant for Depressive Mental States. BMJ,
June 28, 1947, 918-922.
Suzuki, A., Josselyn, S.A., Frankland, P.W., Masushige, S., Silva, A.J., et.al.
(2004). Memory reconsolidation and extinction have distinct temporal and biochemical
signatures. J Neurosci., 24(20), 4787-95.
Tzavara, E.T., Davis, R.J., Perry, K.W., Li, X., Salhoff, C., et.al. (2003). The
CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission
in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol.,
138(4), 544-53.
Vinod, K.Y. & Hungund, B.L. (2006). Role of the endocannabinoid system in depression
and suicide. Trends Pharmacol Sci., 27(10), 539-45.
Viveros, M.P., Marco, E.M., Llorente, R., & López-Gallardo, M. (2007). Endocannabinoid
system and synaptic plasticity: implications for emotional responses. Neural Plast.,
2007:52908.
Volicer, L., Stelly, M., Morris, J., McLaughlin, J., & Volicer, B.J. (1997).
Effects of Dronabinol on Anorexia and Disturbed Behavior in Patients with Alzheimer's
Disease. Int J Ger Psych, 12(9), 913-919.
Zammit, S., Spurlock, G., Williams, H., Norton, N., Williams, N., et.al. (2007).
Genotype effects of CHRNA7, CNR1 and COMT in schizophrenia: interactions with tobacco
and cannabis use. Br J Psychiatry, 191, 402-7.
Zuardi, A.W. (2008). Cannabidiol: from an inactive cannabinoid to a drug with wide
spectrum of action. Rev Bras Psiquiatr., 30(3), 271-80.
Zuardi, A.W, Crippa, J.A., Hallak, J.E., Moreira, F.A., & Guimarães, F.S. (2006).
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med
Biol Res., 39(4), 421-9.
Zuardi, A.W., Shirakawa, I., Finkelfarb, E., & Karniol, I.G. (1982). Action
of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal
subjects. Psychopharmacology, 76(3), 245-50.
Zuardi, A.W., Morais, S.L., Guimaraes, F.S., Mechoulam, R. (1995). Antipsychotic
effect of cannabidiol. Journal of Clinical Psychiatry. 56(10), 485-6.